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Abstract
Purpose. This study investigates the ef® cacy and toxicity of daily oral etoposide in chemotherapy for non-heavily
pretreated advanced and metastatic soft tissue sarcoma (STS).
Subjects. Twenty-seven patients with progressive and measurable disease were treated. Median age was 53 years
(range 20± 71 years) and performance status WHO 0 or 1. Histologies included mainly leiomyosarcoma (8),
malignant ® brous histiocytoma (4), rhabdomyosarcoma (4), liposarcoma (2) and synovial sarcoma (2). Fifteen
patients had received prior radiotherapy, of whom three included sites with haematopoiesis. All patients had received
prior chemotherapy, including adjuvant therapy (7) and mostly consisted of one two-drug schedule (ifosfamide and
doxorubicin) or two single-drug regimens.
Methods. Chemotherapy consisted of etoposide (VP16-213), 50 mg m
2 2 day
2 13 21 q 4 weeks. Blood cell counts
were done weekly. Dose reductions and a maximum delay of 2 weeks was allowed depending on cell counts during
treatment and at the start of a new 4-week treatment cycle.
Results. No objective response was observed. Progressive disease was observed after two treatment cycles in 17/27
patients (68%) and after three cycles in 22/27 patients (81%). The other patients received three to ® ve cycles.
Twenty-four patients went off study due to progressive disease. Grade 3 and 4 neutropenia was observed in eight
and one patients, respectively. Thrombocytopenia grade 3 was seen in two patients. Non-haematological toxicity
grade 3 (nausea, diarrhoea or alopecia) was observed in three patients, and grade 4 (dyspnea, hypotension or
haemorrhage) in three patients.
Discussion. No objective response was obtained. Oral etoposide at a dose of 50 mg m
2 2 day
2 1 3 21 q 4 weeks is
inactive in chemotherapy of pretreated STS. Disease progression occurred within three cycles in the majority (81%)
of patients. Toxicity of this regimen in non-heavily pretreated patients is low.
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Introduction
Etoposide (VP16/213) is a major cytostatic agent
with a broad antitumour spectrum.
1 In clinical prac-
tice, its schedule dependency has been estab-
lished.
1,2 Frequently used schedules are daily
administrations for 3 to 5 days or at days 1, 3 and
5. This schedule dependency prompted clinicians to
examine prolonged administration schedules, in par-
ticular daily oral dosing, for 14± 21 days in 3- or
4-week cycles. This chronic administration proved
to be active in several malignancies including solid
tumours such as breast cancer, gastric cancer,
mesothelioma and Kaposi sarcoma.
1
Interestingly, some tumours, resistant to standard
treatment schedules, responded again following
chronic oral schedules. The EORTC Soft Tissue
and Bone Sarcoma Group and others found no
signi® cant activity of VP16 intravenously at dosages
of 120± 130 mg m
2 2, days 1± 3 or days 1± 5, respect-
ively, every 3 weeks.
3,4 However, most of these
patients were heavily pretreated. The Scandinavian
Sarcoma Group used a combination of ifosfamide
(450 mg m
2 2) and etoposide (600 mg m
2 2) as a
continuous infusion. The 42% response rate was
considered promising by the authors, who also
claimed the effectivity of continuous etoposide
administration.
5
Chronic administration of oral etoposide, planned
dose 150 mg/day for 15 days q 3 weeks, was studied
in 15 heavily pretreated advanced soft tissue sarco-
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mas (STS).
6 No objective responses were observed.
Half of the patients received one cycle only, while
the others received two cycles. Frequently, the daily
dose or the number of treatment days had to be
limited. Based on data of objective responses after
prolonged administration of oral etoposide in non-
heavily pretreated patients, reported by some mem-
bers, the EORTC-STS Group initiated a phase II
study in pre-treated patients who had received one
two-drug schedule or two single drugs only.
Subjects and methods
Subjects
Twenty-seven patients with histologically proven,
progressive, measurable and advanced or metastatic
STS were entered: 15 females, 12 males; median
age 53 years (range 20± 71 years); WHO perform-
ance status grade 0 (10) or grade 1 (17). Most
frequent histologies were leiomyosarcoma (8), ma-
lignant ® brous histiocytoma (4), rhabdomyosar-
coma (4), liposarcoma (2) and synovial sarcoma (2).
Fifteen patients had received prior radiotherapy, of
whom three included sites with haematopoiesis.
All patients had received prior chemotherapy,
including adjuvant therapy (7). This chemotherapy
consisted of one two-drug schedule (usually ifosfa-
mide and doxorubicin) or two single-drug regimens.
Further in- and exclusion criteria were similar to the
standard phase II criteria of the EORTC-STS
Group.
Treatment
Chemotherapy consisted of etoposide (VP16-213)
50 mg m
2 2 day
2 1 orally for 21 consecutive days,
repeated every 4 weeks. Weekly haematological
parameters were determined. If at day 1 of a treat-
ment cycle, white blood cells (WBC) or platelets
were below 3 3 10
9/l or 100 3 10
9/l, respectively,
treatment was delayed until recovery for a maxi-
mum of 2 weeks. If no recovery took place, a dose
reduction was made.
Etoposide treatment was discontinued for 1 week
if during treatment the 3-week cycle WBC fell below
2 3 10
9/l or platelets below 75 3 10
9/l, until recovery
(maximum delay 2 weeks). Dose reductions at the
start of a treatment course were as follows: WBC
2.5± 2.9 3 10
9/l or platelets 75± 99, 25% dose re-
duction; WBC 2.0± 2.4 3 10
9/l or platelets 50± 74,
50% dose reduction; WBC , 2.0 3 10
9/l or platelets
, 50, off study.
Results
No objective response was obtained. After two cy-
cles of treatment, progression was already present in
17/27 patients (68%) and after three cycles in 22/27
patients (81%). The ® ve remaining patients had `no
change’ as their best response and received three to
® ve cycles of treatment. A total of 24 patients went
off study due to tumour progression.
Only one patient experienced grade 4 neutropenia
(patient went off study), eight patients had grade 3
neutropenia, without any fever. Grade 3 thrombocy-
topenia was observed in two patients. One patient
went off study after 2 weeks with a platelet count of
54 3 10
9/l. Grade 4 non-myelotoxicity occurred in
three patients (one pulmonary embolism, one acute
respiratory failure after the ® rst cycle and one gas-
trointestinal bleeding, without thrombocytopeniaÐ
this patient went off study). These latter toxicities
were de® nitely considered to be unrelated to the
chemotherapy.
Discussion
The data presented show that in 27 patients who
had been previously treated with two single-drugs
regimens or one two-drug combination, a regimen
of 3 weeks oral etoposide (50 mg m
2 2 day
2 13 21,
q 4 weeks) failed to achieve an objective response.
Moreover, 22/27 patients (81%) already showed
progressive disease after two or three courses of
treatment. The toxicity of this regimen is low, which
may be explained by the relatively low dose and the
previously received chemotherapy.
Yet, with a similar regimen, Hainsworth et al.
7 in
refractory or resistant patients, reported 2/3 partial
responses. Using higher dosages (3-weekly intra-
venous 130 mg m
2 2) the EORTC-STS Group re-
ported 1/26 patients with a partial response.
3 The
use of higher dosages in a daily oral schedule was
reported by Kampe et al.
6 and resulted in severe
mucositis, gastrointestinal side-effects and myelo-
suppression. No response was seen in the 15 heavily
pretreated patients (no further speci® cations were
given). Discontinuation of treatment and dose re-
ductions were frequently needed in this latter study.
There is hardly any data on etoposide as a single
agent, in ® rst-line treatment for STS. The Scandi-
navian Sarcoma Group used a combination of
etoposide and ifosfamide (both as a continuous in-
fusion) and found a 42% objective response rate. In
second line studies the majority of reports, including
our own, indicate that this drug does not have
signi® cant ef® cacy. The effect of etoposide as a
® rst-line single agent (oral or intravenous) in STS
has yet to be determined.
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